CC-3

CD276xCD3 bispecific antibody · German Cancer Research Center

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CC-3, covering 2025-05-21 to 2025-05-21. Get the full timeline:

Most recent: Clinical Trial Update: FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer [Phase 1]